Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Toolkit
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Toolkit
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
4
Mins
24 Jul 2025
Prognostic Assessment in AL Amyloidosis
Systemic light chain (AL) amyloidosis is a rare plasma cell dyscrasia characterised by the extracellular deposition of misfolded Ig light…
3
Mins
24 Jul 2025
Re-evaluating European Haemophilia Standards
TEST In this feature, the authors critically analyse the European standards for Haemophilia Treatment Centres (HTC), examining their…
1
Mins
24 Jul 2025
Hydroxyurea and Gut Function in Sickle Cell Disease Mice
Sickle cell disease (SCD) is a genetic disorder characterised by chronic inflammation, vaso-occlusion, and endothelial…
24 Jul 2025
The Immunotherapy Landscape for Multiple Myeloma
Take a look at our latest haematology infographic, which explores the current immunotherapy treatment landscape for multiple myeloma…
8
Mins
24 Jul 2025
Rituximab in Adults with Autoimmune Haematological Disorders
Rituximab, a monoclonal anti-CD20 antibody, has proven to be an excellent therapeutic agent for haematological diseases. Low-dose…
1
Mins
24 Jul 2025
Long-Term Outcomes After Allo-HSCT in ALL
Patients (pts) with acute lymphoblastic leukaemia (ALL) in difficult first complete remission (CR) or in second CR, and…
3
Mins
24 Jul 2025
Putting Patients First in Haematology
During the Specialized Working Group session, ‘Quality of Life and Symptoms: Promoting Connection Between Patients and Clinicians’, which…
11
Mins
24 Jul 2025
100 Years of von Willebrand Disease
von Willebrand disease (VWD) is considered the most common inherited bleeding disorder, even surpassing haemophilia A. Nevertheless, VWD…
1
Mins
24 Jul 2025
Microfluidic Testing in Patients with BDUC
In 40–70% of patients referred to a haematologist for the evaluation of an increased bleeding tendency, no diagnosis can…
4
Mins
24 Jul 2025
EHA 2025 Highlights in Acute Lymphoblastic Leukemia
The most important advances in Ph-negative ALL come from the incorporation of immunotherapy into first-line ALL. In this sense…
←
1
2
3
4
5
6
7
8
9
10
…
1,189
1,190
1,191
→
We’ve noticed you’re accessing
from
North/South America.
View
View